Understand the science.
Read the evidence.

Molecular structure, biological function, receptor signaling, and the distinction between endogenous signals and manufactured products. The module establishes the vocabulary used to interpret the rest of the program.

1. 1.1What is a peptide?
2. 1.2Amino acids and peptide bonds
3. 1.3Peptides versus proteins and hormones
4. 1.4Cell receptors and signaling
5. 1.5Endogenous and synthetic peptides
6. 1.6History and therapeutic evolution
7. 1.7Sources, regulation and sport

Pharmacodynamics, exposure over time, administration routes, formulation, and safety. It distinguishes measured properties from claims of clinical equivalence and places calculations within product-specific limits.

1. 2.1Pharmacodynamics
2. 2.2Pharmacokinetics and half-life
3. 2.3Routes of administration
4. 2.4Formulation, stability and storage
5. 2.5Lyophilized products, concentration and volume calculation
6. 2.6Immunogenicity, adverse effects and interactions

Incretin physiology, metabolic research, and interpretation of body-composition outcomes. It examines the population and endpoints behind clinical findings rather than treating related compounds as interchangeable.

1. 3.1Incretin biology
2. 3.2AOD-9604: Community practice and human studies
3. 3.3Multireceptor agonism and research
4. 3.4Patient assessment and follow-up
5. 3.5Cases of obesity, diabetes and bariatric surgery

Growth hormone physiology, GHRH-related compounds, secretagogues, and endocrine risk interpretation. Hormonal responses and changes in IGF-1 are distinguished from demonstrated functional benefits.

1. 4.1Hypothalamus, pituitary gland, GH and IGF-1
2. 4.2CJC-1295 without DAC and sermorelin
3. 4.3Ipamorelin and GH axis secretagogues
4. 4.4Tesamorelin: Community Use and Research
5. 4.5Applications, limitations and endocrine risks
6. 4.6CJC without DAC and ipamorelin: combinations

Melanocortin-related compounds and the product-specific clinical contexts of afamelanotide and bremelanotide. Reported community use, clinical trials, and serious safety signals are examined separately.

1. 5.1Melanotan I and the context of afamelanotide
2. 5.2Melanotan II: Reported Use and Serious Events
3. 5.3PT-141: reported use and bremelanotide as context

Wound-healing biology, matrix research, musculoskeletal outcomes, and the interpretation of named peptide mixtures. Molecular identity, preparation, route, and functional recovery remain distinct questions.

1. 6.1Biology of wound healing
2. 6.2BPC-157 and available evidence
3. 6.3Thymosin beta-4 and TB-500
4. 6.4GHK-Cu and extracellular matrix
5. 6.5Musculoskeletal injuries: cases and critical evaluation
6. 6.6Wolverine, GLOW and KLOW: composition and fixed-mixture proportions

Immune signaling, thymosin alpha-1, antimicrobial peptides, and intestinal inflammation models. Disease-specific evidence and corrected or inconclusive findings are retained when evaluating immune claims.

1. 7.1Immune signaling
2. 7.2Thymosin alpha-1 and antimicrobial peptides
3. 7.3KPV and LL-37: research practice and models
4. 7.4Bowel disease and inflammation: research and clinical boundaries

Neuropeptide signaling and the evidence surrounding cognition, stress, and sleep. Mechanistic or imaging measurements are distinguished from clinically meaningful improvements in the studied population.

1. 8.1Neuropeptides and neurotransmission
2. 8.2Semax: reported use and available evidence
3. 8.3Selank: reported use and available evidence
4. 8.4Cognition, stress, sleep, and clinical evidence

Mitochondrial organization, MOTS-c research, Epitalon, and the limits of longevity biomarkers. It separates cell experiments, animal administration, human physiology, and clinical intervention evidence.

1. 9.1Mitochondrial biology
2. 9.2MOTS-c: Community practice and metabolism
3. 9.3Epitalon: longevity claims and cellular evidence
4. 9.4Biomarkers and limitations of longevity claims

Skin signaling, extracellular-matrix concepts, hair and skin-aging outcomes, and topical safety. Evidence is interpreted at the level of the actual formulation and route.

1. 10.1Skin signaling peptides
2. 10.2Skin and hair aging
3. 10.3Evaluation of efficacy, topical routes and safety

Clinical histories, exposure reconstruction, biomarkers, adverse events, and integrated case interpretation. The focus is documenting and evaluating information rather than deriving unsupported treatment protocols.

1. 11.1Focused clinical history
2. 11.2Assessing patient requests and peptide exposures
3. 11.3Laboratory tests and biomarkers
4. 11.4Comparison of community regimens and evidence
5. 11.5Safe administration and follow-up
6. 11.6Adverse effects and discontinuation
7. 11.7Integrative clinical cases

Comparison of peptide families, polypharmacy, critical appraisal, and integrative cases. The module connects evidence quality, applicability, and uncertainty across the program.

1. 12.1Comparison of families and types of evidence
2. 12.2Interactions and polypharmacy
3. 12.3Interpretation of scientific publications
4. 12.4Discussion of complex cases
5. 12.5Final exam and conclusions